[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557089":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":32,"centralContacts":36,"locations":46,"responsibleParty":190,"collaborators":11,"id":192,"slug":193,"hasResults":194,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":11,"eligibilityCriteria":198,"healthyVolunteers":194,"sex":199,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":11,"studyType":205,"phases":206,"briefSummary":209,"conditions":210,"keywords":224,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":237},{"fullName":5,"class":6},"Vironexis Biotherapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1\u002FGroup 2\u002FGroup 3\u002FGroup 4","EXPERIMENTAL",null,[13,14,15,16],"Genetic: Dose Level 1, VNX-101","Genetic: Dose Level 2, VNX-101","Genetic: Dose Level 3, VNX-101","Genetic: Dose Level 4, VNX-101",[18,23,26,29],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"GENETIC","Dose Level 1, VNX-101","Adeno-associated viral vector encoding the CD3\u002FCD19 Bi-Specific T-Cell Engager (AAV.CD3\u002FCD19), Single IV infusion",[9],{"type":19,"name":24,"description":21,"armGroupLabels":25,"otherNames":11},"Dose Level 2, VNX-101",[9],{"type":19,"name":27,"description":21,"armGroupLabels":28,"otherNames":11},"Dose Level 3, VNX-101",[9],{"type":19,"name":30,"description":21,"armGroupLabels":31,"otherNames":11},"Dose Level 4, VNX-101",[9],[33],{"name":34,"affiliation":5,"role":35},"Vironexis Clinical Trials","STUDY_DIRECTOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Allen Reha","CONTACT","908-938-6019","allen.reha@vironexis.com",{"name":43,"role":39,"phone":44,"phoneExt":11,"email":45},"Recruitment Partner: PatientWing","213-459-2979","studies@patientwing.com",[47,68,82,96,115,130,145,160,175],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-117.97729,34.13945,{"lat":59,"lon":58},[62,66],{"name":63,"role":39,"phone":64,"phoneExt":11,"email":65},"Anthony Stein, MD","877-467-3411","AStein@coh.org",{"name":63,"role":67,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":69,"status":49,"city":70,"state":51,"zip":71,"country":53,"countryCode":54,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Valkyrie Clinical Trials","Los Angeles","90067",{"type":56,"coordinates":73},[74,75],-118.24368,34.05223,{"lat":75,"lon":74},[78],{"name":79,"role":39,"phone":80,"phoneExt":11,"email":81},"Myo Zaw","424-535-1874","clinicaltrials@vctcare.com",{"facility":83,"status":49,"city":84,"state":85,"zip":86,"country":53,"countryCode":54,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Colorado Blood Cancer Institute","Denver","Colorado","80218",{"type":56,"coordinates":88},[89,90],-104.9847,39.73915,{"lat":90,"lon":89},[93],{"name":94,"role":39,"phone":95,"phoneExt":11,"email":11},"Clinical Trial Information Line","720-754-4835",{"facility":97,"status":49,"city":98,"state":99,"zip":100,"country":53,"countryCode":54,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"New York Medical College","Valhalla","New York","10595",{"type":56,"coordinates":102},[103,104],-73.77513,41.07482,{"lat":104,"lon":103},[107,111,114],{"name":108,"role":39,"phone":109,"phoneExt":11,"email":110},"Mitchell Cairo, MD","914-594-2150","mitchell_cairo@nymc.edu",{"name":112,"role":39,"phone":11,"phoneExt":11,"email":113},"Lauren Harrison","lauren_harrison@nymc.edu",{"name":108,"role":67,"phone":11,"phoneExt":11,"email":11},{"facility":116,"status":49,"city":117,"state":118,"zip":119,"country":53,"countryCode":54,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"University of North Carolina at Chapel Hill\u002F University of North Carolina Medical Center","Chapel Hill","North Carolina","27599",{"type":56,"coordinates":121},[122,123],-79.05584,35.9132,{"lat":123,"lon":122},[126],{"name":127,"role":39,"phone":128,"phoneExt":11,"email":129},"Lacey Williams, MD","919-445-9676","Lacey_Williams@med.unc.edu",{"facility":131,"status":49,"city":132,"state":133,"zip":134,"country":53,"countryCode":54,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"The Ohio State University Wexner Medical Center","Columbus","Ohio","43210",{"type":56,"coordinates":136},[137,138],-82.99879,39.96118,{"lat":138,"lon":137},[141],{"name":142,"role":39,"phone":143,"phoneExt":11,"email":144},"Gregory Behbehani, MD, PhD","614-293-3316","gregory.behbehani@osumc.edu",{"facility":146,"status":49,"city":147,"state":148,"zip":149,"country":53,"countryCode":54,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Oregon Health & Science University","Portland","Oregon","97239",{"type":56,"coordinates":151},[152,153],-122.67621,45.52345,{"lat":153,"lon":152},[156],{"name":157,"role":39,"phone":158,"phoneExt":11,"email":159},"Knight Cancer Institute Clinical Trials","503-949-1080","trials@ohsu.edu",{"facility":161,"status":49,"city":162,"state":163,"zip":164,"country":53,"countryCode":54,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"TriStar BMT","Nashville","Tennessee","37203",{"type":56,"coordinates":166},[167,168],-86.78444,36.16589,{"lat":168,"lon":167},[171],{"name":172,"role":39,"phone":173,"phoneExt":11,"email":174},"Stephen Strickland, MD","615-329-7274","stephen.strickland@hcahealthcare.com",{"facility":176,"status":49,"city":177,"state":178,"zip":179,"country":53,"countryCode":54,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":56,"coordinates":181},[182,183],-95.36327,29.76328,{"lat":183,"lon":182},[186],{"name":187,"role":39,"phone":188,"phoneExt":11,"email":189},"Nicholas J Short, MD","713-563-4485","NShort@Mdanderson.org",{"type":191,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100557089","phase-1-gene-therapy-for-cd19-positive-hematologic-malignancies-sentry-cd19-100557089",false,"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","A Phase 1\u002F2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)","Inclusion Criteria:\n\n* Age: Part 1: 18-90 years of age, Part 2: 13-90 years of age\n* Relapsed or refractory CD-19 positive leukemia or lymphoma as defined in the protocol\n* CD19-positive expression\n* AAV specified capsid total antibody \\\u003C1:400\n* Protocol-specified ranges for renal, liver, cardiac and pulmonary function\n* Protocol-specified ranges for hematology parameters\n\nExclusion Criteria:\n\n* Hepatoxicity (AST or ALT \\> 2x upper limit of normal)\n* History of thrombotic microangiopathy or cardiomyopathy, or evidence of sensory neuropathy\n* Pregnant or nursing (lactating) women\n* Acute Graft versus Host Disease (GvHD): Grade 2-4 or chronic GvHD of any grade\n* History of hypersensitivity to corticosteroids or history of corticosteroid-related toxicity\n* Chemotherapy given within the protocol-specified discontinuation timelines\n\nOther Inclusion\u002FExclusion criteria to be applied per protocol.","ALL","13 Years","90 Years",{"count":203,"type":204},32,"ESTIMATED","INTERVENTIONAL",[207,208],"PHASE1","PHASE2","This is a Phase 1\u002F2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.",[211,212,213,214,215,216,217,218,219,220,221,222,223],"B-cell Acute Lymphoblastic Leukemia","Large B-cell Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Marginal Zone Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma","Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Burkitt Lymphoma","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Non Hodgkin Lymphoma","Mixed Phenotype Acute Leukemia",[225,226,227],"CD19-positive","Leukemia","Lymphoma","2026-03-24",{"date":230,"type":231},"2026-03-30","ACTUAL",{"date":233,"type":231},"2025-05-30",{"date":235,"type":204},"2031-09",{"name":5,"class":6},9]